08:00 - 08:40

Registration and Coffee

Showing of Streams
12:20 - 13:40

Lunch Provided for Full-Day Workshop Attendees Only (Those registered for both workshop A and workshop B)

Showing of Streams
08:00 - 08:40 40 mins
Registration and Coffee
08:40 - 08:45 5 mins
Workshop A: The Nuts and Bolts of Antibodies
Workshop Moderator's Remarks
  • Moderator Mahendra Deonarain, PhD - Chief Executive and Science Officer, Antikor Biopharma Ltd
more
08:45 - 09:15 30 mins
Workshop A: The Nuts and Bolts of Antibodies
Display Technology and Antibody Discovery
  • John McCafferty, PhD - CEO and Founder, IONTAS
more
09:15 - 09:45 30 mins
Workshop A: The Nuts and Bolts of Antibodies
Antibody Fragments and How to Make Them Work as ADCs
  • Mahendra Deonarain, PhD - Chief Executive and Science Officer, Antikor Biopharma Ltd
more

Antibody fragments like single-chain Fvs have long been thought of as a stepping stone to antibody-based therapeutics. ScFvs are often rebuilt into larger formats as they are viewed as being too small and are cleared from the body too quickly to make viable therapeutics. This presentation will show that scFvs, suitably engineered and conjugated to payloads can make effective drug candidates on their own and the clearance and penetration properties could be a better way to apply them in the field of antibody drug conjugates for solid tumours. Novel concepts in antibody discovery, structure, functions and bio-conjugation will be covered with a view to making effective FDCs (Fragment Drug Conjugates).

09:45 - 10:15 30 mins
Workshop A: The Nuts and Bolts of Antibodies
Preclinical "Humanized" Tumor Models for the Characterisation of Functional Antibodies and Drug Conjugates
  • Jens Hoffmann, PhD - CEO, EPO Berlin-Buch GmbH (EPO)
more

To overcome the current constraints in preclinical evaluation of functional antibodies for cancer immune therapy we have developed PDX models on mice with a functional human immune system. At the time when the human immune system is developed, established patient-derived xenografts (PDX) were transplanted on these humanised mice, enabling appropriate preclinical studies on tumor immune biology, evaluation of new immune therapies and combinations, as well as the identification and validation of biomarkers for tumor immune therapy.

10:15 - 10:45 30 mins
Workshop A: The Nuts and Bolts of Antibodies
Networking Refreshment Break
10:45 - 11:15 30 mins
Workshop A: The Nuts and Bolts of Antibodies
Fundamentals of Mass Spectrometry in the Analysis of Protein Therapeutics
  • Ewald van den Bremer, PhD - Senior Scientist, Genmab BV
more

Modern mass spectrometry (MS) has become a powerful technology in life sciences and provides unprecedented insights into the composition, structure and function of complex biopharmaceuticals. This workshop will describe the principles underlying MS-based strategies and the wide range of applications of MS to structurally and functionally assess proteins, and antibodies in particular.

11:15 - 11:45 30 mins
Workshop A: The Nuts and Bolts of Antibodies
Fc-mediated Effector Functions and Engineering Strategies for Specific Modulation
  • Matthias Peipp, PhD - Professor and Head of Research, Christian-Albrechts-University Kiel
more

Monoclonal antibodies are able trigger various Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and phagocytosis. With a focus on cancer therapy the relative contribution of selected effector functions to therapeutic activity and engineering strategies to rationally design antibodies with tailor-made effector functions will be discussed.    

11:45 - 12:15 30 mins
Workshop A: The Nuts and Bolts of Antibodies
IgA As a Novel Isotype for Treatment of Lymphoma and Neuroblastoma
  • Jeanette Leusen, PhD - Associate Professor, Head Immunotherapy Group, UMC Utrecht
more

All therapeutic antibody in the clinic are of the IgG class. But IgA has great potential in vitro, it recruits neutrophils with a different mode of action. With a panel of new antibodies against CD20 for lymphoma and against GD2 for neuroblastoma we see clear advantages in preclinical models.

12:15 - 12:20 5 mins
Workshop A: The Nuts and Bolts of Antibodies
Close of Workshop A
12:20 - 13:40 80 mins
Lunch Provided for Full-Day Workshop Attendees Only (Those registered for both workshop A and workshop B)
13:40 - 13:45 5 mins
Workshop B: CAR-T & anti-CD3-based Bispecifics
Workshop Moderators' Remarks
  • Moderator Kerry Chester, PhD - Professor of Molecular Medicine, UCL Cancer Institute
  • Moderator David Gilham, PhD - Vice President of Research & Development, Celyad S.A.
more
13:45 - 14:15 30 mins
Workshop B: CAR-T & anti-CD3-based Bispecifics
CAR-T Design Theory to Practice
  • Martin Pule, PhD - Senior Lecturer in Haematology, University College London
more
14:15 - 14:45 30 mins
Workshop B: CAR-T & anti-CD3-based Bispecifics
Engineering the NKG2D Receptor to Enable CAR T Cell Therapy of Cancer
  • David Gilham, PhD - Vice President of Research & Development, Celyad S.A.
more

Natural Killer group 2D (NKG2D) is a NK activatory receptor that binds to 8 stress-inducible ligands which are known to be over-expressed in cancer. A CAR consisting of the fusion of the NKG2D protein with CD3z enables T cells to target these stress ligands and is currently being tested in phase I clinical trial. Our on-going work is seeking to understand how further engineering of the NKG2D CAR alters the functionality of receptor.

14:45 - 15:15 30 mins
Workshop B: CAR-T & anti-CD3-based Bispecifics
IL-18 Induces T-bet(High) FoxO1(Low) T cells with Improved Activity in the CAR T cell Therapy of Advanced Solid Tumors
  • Hinrich Abken, MD, PhD - Professor of Cancer Genetics and Immunology, University of Cologne
more

CAR T cells with inducible IL-18 release showed T-bet(high) FoxO1(low) signature, induced an overall change in the tumor immune cell landscape, showed superior activity against large established tumors of pancreatic and lung cancer.

15:15 - 15:45 30 mins
Workshop B: CAR-T & anti-CD3-based Bispecifics
Networking Refreshment Break
15:45 - 16:15 30 mins
Workshop B: CAR-T & anti-CD3-based Bispecifics
ADAPTIR Platform: Rapid Development of Novel and Manufacturable Bispecific Therapeutics
  • David Bienvenue, PhD - Senior Director, Protein Sciences, Aptevo Therapeutics
more

The presentation will highlight the activity, stability and manufacturability of ADAPTIR bispecifics and include recent data for a lead preclinical candidate, APVO436, which targets CD123 and CD3. APVO436 has shown potent biological activity in preclinical studies and is rapidly advancing towards first-in-human clinical trials. The presentation will also cover Aptevo's other pipeline candidates, including APVO414 (PSMA x CD3) and ALG.APV.527 (4-1BB x 5T4).

16:15 - 16:45 30 mins
Workshop B: CAR-T & anti-CD3-based Bispecifics
Late Breaking Presentation
16:45 - 17:15 30 mins
Workshop B: CAR-T & anti-CD3-based Bispecifics
Panel Discussion
17:15 - 17:20 5 mins
Workshop B: CAR-T & anti-CD3-based Bispecifics
Close of Workshop B

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。